 BidaskClub downgraded shares of Celldex Therapeutics NASDAQ:CLDX from a buy rating to a hold rating in a research note released on Wednesday, BidAskClub reports. A number of other research firms also recently commented on CLDX. HC Wainwright restated a buy rating and set a 16.00 price objective down from 19.00 on shares of Celldex Therapeutics ... 